| Primary |
| Constipation |
30.0% |
| Product Used For Unknown Indication |
25.8% |
| Drug Use For Unknown Indication |
9.2% |
| Hepatic Encephalopathy |
5.0% |
| Hypertension |
4.2% |
| Electrolyte Imbalance |
3.3% |
| Schizophrenia |
3.3% |
| Bipolar Disorder |
2.5% |
| Poor Quality Sleep |
2.5% |
| Cardiac Operation |
1.7% |
| Constipation Prophylaxis |
1.7% |
| Hepatitis |
1.7% |
| Laxative Abuse |
1.7% |
| Liver Disorder |
1.7% |
| Pain |
1.7% |
| Constipation |
0.8% |
| Agitation |
0.8% |
| Ammonia Increased |
0.8% |
| Ascites |
0.8% |
| Blood Glucose Increased |
0.8% |
|
| Vomiting |
9.3% |
| Drug Ineffective |
7.4% |
| Jaundice |
7.4% |
| Therapeutic Agent Toxicity |
7.4% |
| Weight Decreased |
7.4% |
| Gastrointestinal Haemorrhage |
5.6% |
| Tracheo-oesophageal Fistula |
5.6% |
| Urinoma |
5.6% |
| Bronchospasm |
3.7% |
| Gastroenteritis |
3.7% |
| Hypersensitivity |
3.7% |
| Ileus |
3.7% |
| Melaena |
3.7% |
| Pharmaceutical Product Complaint |
3.7% |
| Pneumonia |
3.7% |
| Product Quality Issue |
3.7% |
| Renal Failure |
3.7% |
| Sensation Of Foreign Body |
3.7% |
| Tremor |
3.7% |
| Urinary Tract Infection |
3.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
32.0% |
| Product Used For Unknown Indication |
26.1% |
| Hypertension |
6.7% |
| Systemic Lupus Erythematosus |
3.6% |
| Constipation |
3.0% |
| Drug Exposure During Pregnancy |
3.0% |
| Schizophrenia |
3.0% |
| Ill-defined Disorder |
2.9% |
| Pain |
2.7% |
| Diabetes Mellitus |
2.6% |
| Type 2 Diabetes Mellitus |
2.5% |
| Urinary Tract Infection |
2.4% |
| Chronic Obstructive Pulmonary Disease |
2.1% |
| Depression |
1.6% |
| Hyperemesis Gravidarum |
1.5% |
| Pneumonia |
1.5% |
| Drug Therapy |
0.9% |
| Infection |
0.7% |
| Nutritional Support |
0.7% |
| Crohn's Disease |
0.7% |
|
| Toxic Epidermal Necrolysis |
12.5% |
| Mesothelioma |
9.8% |
| Teratogenicity |
8.9% |
| Pancreatic Carcinoma |
8.0% |
| Therapeutic Agent Toxicity |
8.0% |
| Jaundice |
7.6% |
| Urinary Tract Infection |
5.4% |
| White Blood Cell Count Increased |
5.4% |
| Pain |
4.0% |
| Constipation |
3.1% |
| Drug Interaction |
3.1% |
| Emphysema |
3.1% |
| Maternal Exposure During Pregnancy |
3.1% |
| Urinoma |
3.1% |
| Vomiting |
3.1% |
| Stevens-johnson Syndrome |
2.7% |
| Diarrhoea |
2.2% |
| Hypertension |
2.2% |
| Maternal Drugs Affecting Foetus |
2.2% |
| Non-hodgkin's Lymphoma |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.7% |
| Drug Use For Unknown Indication |
19.5% |
| Constipation |
8.0% |
| Pain |
6.1% |
| Prophylaxis |
5.9% |
| Hypertension |
4.6% |
| Multiple Myeloma |
2.8% |
| Depression |
2.3% |
| Nausea |
2.2% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| Hepatic Neoplasm Malignant |
1.5% |
| Non-small Cell Lung Cancer |
1.5% |
| Diabetes Mellitus |
1.5% |
| Hepatitis C |
1.5% |
| Rheumatoid Arthritis |
1.4% |
| Insomnia |
1.3% |
| Back Pain |
1.2% |
| Schizophrenia |
1.2% |
| Gastrooesophageal Reflux Disease |
1.1% |
| Osteoporosis |
1.1% |
|
| Vomiting |
16.0% |
| Weight Decreased |
8.6% |
| Death |
8.0% |
| Thrombocytopenia |
6.0% |
| Sepsis |
5.8% |
| White Blood Cell Count Decreased |
5.4% |
| Pyrexia |
5.3% |
| Pneumonia |
4.9% |
| Urinary Tract Infection |
4.5% |
| Renal Failure Acute |
4.5% |
| Syncope |
3.8% |
| Hepatic Encephalopathy |
3.7% |
| Renal Failure |
3.5% |
| White Blood Cell Count Increased |
3.4% |
| Tremor |
3.1% |
| Weight Increased |
2.9% |
| Dyspnoea |
2.8% |
| Somnolence |
2.7% |
| Constipation |
2.6% |
| Neutropenia |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
34.6% |
| Acute Promyelocytic Leukaemia |
7.7% |
| Constipation |
7.7% |
| Depression |
7.7% |
| Parkinson's Disease |
7.7% |
| Arthritis |
3.8% |
| Back Pain |
3.8% |
| Chronic Obstructive Pulmonary Disease |
3.8% |
| Cystitis |
3.8% |
| Gastric Disorder |
3.8% |
| Hypertension |
3.8% |
| Infection |
3.8% |
| Smoking Cessation Therapy |
3.8% |
| Vitamin Supplementation |
3.8% |
|
| Blood Glucose Increased |
16.7% |
| Drug Interaction |
16.7% |
| Haemorrhoidal Haemorrhage |
16.7% |
| Myositis |
16.7% |
| Nausea |
16.7% |
| Parkinsonism |
16.7% |
|
